Newsroom | Cellworks

Newsroom

Cellworks Enhances TRI with Personalized Tumor Microenvironment Modeling to Predict Overall Survival in NSCLC Patients Receiving Immunotherapy

HOUSTON, Texas, November 12, 2024

Cellworks Biosimulation Combined with Tumor Microenvironment Modeling Enhances Predictions of IO Response in NSCLC Patients

BARCELONA, Spain, September 16, 2024

Cellworks Biosimulation Predicts PARPi Benefit in Patients with Ovarian, Pancreatic, Prostate and Triple-Negative Breast Cancers

BARCELONA, Spain, September 16, 2024

Cellworks Biosimulation Identifies which NSCLC Patients will Benefit from Combining Chemotherapy with Immunotherapy

SAN DIEGO, CA, September 11, 2024

Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations

SAN DIEGO, CA, September 9, 2024

Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified Lab

SOUTH SAN FRANCISCO, May 28, 2024

Cellworks Personalized Therapy Biosimulation Study Produces Superior OS and DFS Predictions for Gastroesophageal Cancer Patients

SOUTH SAN FRANCISCO, March 11, 2024

Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets

SOUTH SAN FRANCISCO, January 9, 2023

ASH 2022: Cellworks Biosimulation Study Reveals Biomarkers that Predict Response to Hypomethylating Agents and Patient Survival in MDS

SOUTH SAN FRANCISCO, December 12, 2022

Cellworks Therapy Biosimulation Study Reveals Promising New Biomarkers for TMZ Resistance in Glioblastoma Patients

SOUTH SAN FRANCISCO, November 22, 2022

Cellworks Wins Dell Technologies The Challengers 2022 Innovative Business of the Year Award

SOUTH SAN FRANCISCO, Calif., September 7, 2022

Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-guideline Genomic Factors

SOUTH SAN FRANCISCO, Calif., August 9, 2022

ASCO 2022 : Cellworks Singula™ TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies

CHICAGO, June 6, 2022

ASCO 2022 : Cellworks Singula™ TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors

CHICAGO, June 6, 2022

ASH 2021: myCare-023 Finds Cellworks Personalized Biosimulation a Stronger Predictor of Therapy Response for AML Patients than Physician Prescribed Treatment

ATLANTA, Georgia, December 14, 2021

ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in AML Patients

ATLANTA, Georgia, December 14, 2021

ASH 2021: Cellworks Personalized Therapy Biosimulation Study Identifies Novel Biomarkers Predictive of Response in Resistance Cases of MCL

ATLANTA, Georgia, December 14, 2021

ASH 2021: Cellworks Personalized Biosimulation Study Identifies Novel MDS Biomarkers and Immune Modulation Predictive of Therapy Response

ATLANTA, Georgia, December 14, 2021

WCLC 2021 : Cellworks Clinical Trial Results Presented at IASLC 2021
World Conference on Lung Cancer

SOUTH SAN FRANCISCO, Calif., September 13, 2021

ASCO 2021 : Cellworks Singula™ Delivers Superior OS and DFS Predictions for Brain Cancer Patients in myCare-022-03 Clinical Trial

SOUTH SAN FRANCISCO, Calif., June 4, 2021

ASCO 2021 : Cellworks CBM Clinical Study Identifies Novel Biomarkers for ATRA Benefit and Failure in AML Patients

SOUTH SAN FRANCISCO, Calif., June 4, 2021

ASCO 2021 : Cellworks Singula™ Accurately Predicts Clinical Outcome from Treatments in Patients with NSCLC

SOUTH SAN FRANCISCO, Calif., June 4, 2021

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trials Achieve 90% Therapy Response Prediction Accuracy for AML and MDS Patients

SOUTH SAN FRANCISCO, Calif., December 7, 2020

ASH 2020 : Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

SOUTH SAN FRANCISCO, Calif., December 7, 2020

ASH 2020 : Cellworks CBM Biosimulation Identifies Genomic Causes for Induction Failure in AML Patients and Suggests Alternative Therapies

SOUTH SAN FRANCISCO, Calif., December 7, 2020

ASH 2020 : Cellworks CBM Identifies Genomic Signatures Impacting HOXA Regulation that Determine Response for AML Patients with
Monosomy 7

SOUTH SAN FRANCISCO, Calif., December 7, 2020

ASCO 2020 : myCare Clinical Studies Show Cellworks Singula™Achieves Superior Therapy Response Predictions for Brain Cancer Patients

SOUTH SAN FRANCISCO, Calif., May 29, 2020

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for AML and MDS Patients with Higher Accuracy than Physician Prescribed Treatments

SOUTH SAN FRANCISCO, Calif., May 14, 2020

ASCO 2020 : Cellworks Singula™ Predicts Personalized Therapy Responses for Pancreatic Cancer Patients with 94% Accuracy

SOUTH SAN FRANCISCO, Calif., May 14, 2020

Blood Advances Publishes Cellworks Prospective Genomic Biosimulation Study that Predicts Cancer Therapy Response with 90% Accuracy

SAN FRANCISCO, Sept. 19, 2019 (GLOBE NEWSWIRE)

ASCO 2019 : Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions

CHICAGO, 2019 ASCO Annual Meeting, June 3, 2019

ASH 2018 : Cellworks Study Predicted Non-Response to Azacitidine in MDS Patients with 100% Accuracy using AI-Driven Biosimulation

SAN DIEGO, Calif. December 2, 2018

ASH 2018 : Cellworks AI-Driven Biosimulation Predicted Chemo-resistance in AML and MDS Patients with 90% Accuracy

SAN DIEGO, Calif. December 2, 2018

Cellworks to Present 10 Abstracts at 2018 American Society of Hematology Annual Meeting

SAN JOSE, Calif. November 19, 2018

Former UnitedHealth Group Cancer Director Dr. Lee Newcomer Joins Cellworks Board of Directors

SAN JOSE, Calif., October 17, 2018

Dr. Allen Lichter Joins Cellworks Group Board of Directors

SAN JOSE, Calif., May 31, 2018

Top